Nice post Saltz. Yes, I do want to see some stellar and compelling Adjunct PE data.. It will also be reassuring that we are granted BTD. I shared some slides yesterday that demonstrated BTD approvals = 90% ongoing FDA marketed approvals. However, if not BTD approved..many still were eventually granted FDA marketing approval..especially the compounds that had a Fast Tract status. Let's get Adjunct locked and Loaded..then on to more lucrative valuations. Obviously, one catalyst at a time will build value in this equity. I am very disappointed in the volume of shares being traded Post CROI (i.e..Interest)...what is up with that?
Market Data 
Markets 
AI
